Rakovina Therapeutics Announces Results from 2025 Annual General Meeting

Core Points - Rakovina Therapeutics Inc. held its 2025 annual general meeting of shareholders on June 25, 2025, in Vancouver, British Columbia [1] - All five nominated members of the board of directors were elected: Jeffrey Bacha, Dr. Dennis Brown, Alfredo De Lucrezia, Yevgeniy Meshcherekov, and Dr. David Kideckel [2] - Shareholders approved the re-appointment of Davidson & Company LLP as the auditor until the next annual general meeting, set the number of directors at five, and re-approved the existing omnibus equity incentive plan [3] Company Overview - Rakovina Therapeutics is a biopharmaceutical research company focused on developing innovative cancer treatments using AI-powered drug discovery [4] - The company has established a pipeline of DNA-damage response inhibitors aimed at advancing drug candidates into human clinical trials in collaboration with pharmaceutical partners [5]